key: cord-1004647-lvyf3vq0 authors: Abreu, Rodrigo; Miguel, Renata; Saieg, Mauro title: Subacute (De Quervain) thyroiditis during the COVID‐19 pandemic date: 2021-05-10 journal: Cancer Cytopathol DOI: 10.1002/cncy.22449 sha: 623d3b678d64250c8ddb69b64aef186bb0e1e0aa doc_id: 1004647 cord_uid: lvyf3vq0 Coronavirus disease 2019 (COVID‐19) is a new disease whose clinical presentation and potential complications are not yet fully understood. One of these possible reported complications is the onset of subacute (De Quervain) thyroiditis (SAT). Here a series of cases of SAT during the COVID‐19 pandemic are reported, and a possible correlation between these 2 entities is extrapolated. The cytological pictures of all 3 cases were very similar, and they all showed clusters of epithelioid histiocytes forming loose granulomas and scattered giant cells amid rare inflammatory and follicular cells (Fig. 1) . They were compatible with the classic cytological examination, which typically presents granulomas along with many multinucleated giant cells. Cellularity, however, is variable and depends on the stage of the disease. In the early stages, there are more neutrophils and eosinophils, which are reminiscent of acute thyroiditis. The late stages are hypocellular and show giant cells surrounding and engulfing colloid in addition to epithelioid cells, lymphocytes, and scant degenerated follicular cells. 10, 11 In previously reported cases in the literature, similarly to our reported experience, the majority of patients were female with an average age of 35 years (range, 18-43 years). Patients were mostly treated with corticotherapy for approximately 4 weeks and had good outcomes. [3] [4] [5] [6] [7] 12 The average time between the confirmation of infection and FNA was 25 days (range, 9-42 days). [4] [5] [6] [7] 12 The most common symptoms included cervical pain with irradiation to the jaw, asthenia, and palpitation. Importantly, these symptoms could be confused with those commonly associated with sepsis, cardiopulmonary dysfunction, or even progression of the respiratory syndrome caused by COVID-19 7 ; therefore, SAT should be included in the clinical differential diagnosis as a possible complication in these patients. Although the pathophysiology of possibly COVID-associated SAT has not yet been fully explored, angiotensin-converting enzyme 2 (ACE-2) messenger RNA has been detected recently by reverse transcriptasepolymerase chain reaction in human follicular thyroid cells. Because ACE-2 is the receptor for the cellular entry of SARS-CoV-2, this could partially explain the onset of COVID-19-related SAT by direct virial tissue damage. 13 As a matter of fact, many changes attributed to SARS-CoV-2 infection have been described in several organs besides the respiratory system 14-16 (eg, dermatological and cardiac disorders; kidney, neural, and gastrointestinal disorders 2,16-18 ; and diabetogenic effects 19 ) To document a possible increase in the cases of SAT during the pandemic period, we also collected data on all cases of SAT diagnosed via FNA in 2019 and 2020. We observed 11 cases in 2019 (0.04% of total cases) and 15 in 2020 (0.07% of total cases). Although there was a slight increase in number potentialized by the decrease in cases in 2020 due to the lockdown established by local authorities, 20 this difference was not statistically significant. In addition, laboratory confirmation of SARS-CoV-2 infection was seen for only 3 of the cases, and this limits a cause-effect association. Larger future studies with robust correlations between pathological, clinical, and imaging data of COVID-19-associated SAT, as well as molecular and microbiological confirmation of the virus in the thyroid tissue, are needed to further elucidate its pathophysiology and clarify this possible, intriguing association. In conclusion, although SAT is a self-limited inflammatory condition of the thyroid gland with a usually benign course, its symptoms could be confused with those of COVID-19's worrisome progression. Knowledge of a possible association between these 2 entities is, therefore, of the utmost importance in the current epidemic scenario and could help us to achieve accurate diagnoses and proper therapy for these patients. No specific funding was disclosed. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Clinical characteristics of coronavirus disease 2019 in China A case of subacute thyroiditis associated with Covid-19 infection Subacute thyroiditis in a patient infected with SARS-COV-2: an endocrine complication linked to the COVID-19 pandemic Subacute thyroiditis after SARS-COV-2 infection Is subacute thyroiditis an underestimated manifestation of SARS-CoV-2 infection? Insights from a case series Subacute thyroiditis associated with COVID-19 Viruses and thyroiditis: an update Cellular composition of subacute thyroiditis. an immunohistochemical study of six cases Fineneedle aspiration of subacute granulomatous thyroiditis (De Quervain's thyroiditis): a clinico-cytologic review of 36 cases Bethesda System for Reporting Thyroid Cytopathology Subacute thyroiditis associated with COVID-19 Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis Acute, subacute, and chronic Corner points of the diagnosis. Article in Hungarian Extrapulmonary manifestations of COVID-19 A comprehensive review of manifestations of novel coronaviruses in the context of deadly COVID-19 global pandemic Extrapulmonary and atypical clinical presentations of COVID-19 New-onset diabetes in Covid-19 Global impact of the COVID-19 pandemic on cytopathology practice: results from an international survey of laboratories in 23 countries The authors made no disclosures.